Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Ortojorjia | Pharma | 36.6% | 86th pct | 110 |
| SBC Global | Pharma | 25.4% | 69th pct | 110 |
| Vorld Pharma | Pharma | 10.0% | 36th pct | 110 |
| Kalandadze | Pharma | -5.4% | 7th pct | 110 |
| Geo - Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Vorld Pharma | Ortojorjia | Kalandadze | SBC Global | Geo - Pharma |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 66.1% | 58.1% | 10.3% | 28.7% | — |
| EBITDA Margin | 10.0% | 36.6% | -5.4% | 25.4% | — |
| EBITDAR | 310 | 979 | -83 | 572 | — |
| EBITDAR Margin | 11.5% | 36.6% | -3.6% | 27.1% | — |
| EBIT Margin | 8.7% | 35.9% | -6.0% | 24.9% | — |
| Net Profit Margin | 3.8% | 35.7% | -6.4% | 24.1% | — |
| Operating Expense % of Sales | 56.1% | 21.5% | 15.7% | 3.3% | — |
| Returns | |||||
| Return on Assets (ROA) | 2.2% | 30.7% | -24.5% | 35.9% | — |
| Return on Equity (ROE) | 4.1% | 32.5% | -49.4% | 50.4% | — |
| ROIC [EBIT / Invested Capital] | 7.4% | 51.6% | -47.3% | 52.8% | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 16.7% | 5.5% | 0.0% | 0.0% | — |
| Debt-to-Equity | 0.32x | 0.06x | 0.00x | 0.00x | — |
| Debt-to-EBITDA | 2.97x | 0.17x | N/A | 0.00x | — |
| Equity-to-Assets | 52.2% | 94.5% | 49.7% | 71.4% | — |
| Net Debt | 680 | -1,075 | -7 | -13 | — |
| Cash & Equivalents | 120 | 1,244 | 7 | 13 | — |
| Total Debt | 800 | 170 | N/A | N/A | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.56x | N/A | 1.36x | 3.49x | — |
| Quick Ratio | 0.56x | N/A | 1.36x | 3.49x | — |
| Cash Ratio | 0.05x | N/A | 0.02x | 0.03x | — |
| Total Current Assets | 1,286 | 3,032 | 416 | 1,403 | — |
| Total Current Liabilities | 2,280 | N/A | 305 | 402 | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 1,286 | 1,006 | 3 | 482 | — |
| Trade Payables | 966 | N/A | 305 | 402 | — |
| Net Working Capital | -994 | 3,032 | 110 | 1,001 | — |
| Net Working Capital % of Revenue | -36.8% | 113.3% | 4.8% | 47.5% | — |
| Trade Working Capital | 320 | 1,006 | -302 | 81 | — |
| Trade Working Capital % of Revenue | 11.8% | 37.6% | -13.0% | 3.8% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 2.10x | 2.66x | 689.46x | 4.37x | — |
| Days Sales Outstanding (DSO) | 173.8 | 137.2 | 0.5 | 83.6 | — |
| Payables Turnover | 0.95x | N/A | 6.80x | 3.74x | — |
| Days Payable Outstanding (DPO) | 384.5 | N/A | 53.7 | 97.7 | — |
| Cash Conversion Cycle | -210.8 days | 137.2 days | -53.1 days | -14.1 days | — |
| Asset Turnover | 0.56x | 0.86x | 3.81x | 1.49x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 3,727 | 2,657 | N/A | 1,747 | — |
| Free Cash Flow (OCF − Capex proxy) | -320 | 2,657 | N/A | 1,747 | — |
| Cash Conversion (OCF / EBITDA) | 1383.6% | 271.3% | N/A | 326.1% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |